

**TITAN MEDICAL INC.**  
**Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018 and 2017**

**(IN UNITED STATES DOLLARS)**

**TITAN MEDICAL INC.**  
**Unaudited Condensed Interim Balance Sheets**  
**As at September 30, 2018 and December 31, 2017**  
**(In U.S. Dollars)**

	Note	September 30, 2018	December 31, 2017
<b>Assets</b>			
Current Assets:			
Cash and cash equivalents		\$ 29,230,819	\$ 26,130,493
Amounts receivable		111,150	75,151
Deposits	6	4,278,850	2,538,434
Prepaid expense		636,542	149,593
<b>Total Current Assets</b>		<b>\$ 34,257,361</b>	<b>\$ 28,893,671</b>
Furniture and Equipment		-	6,714
Patent Rights	3	956,360	774,225
<b>Total Assets</b>		<b>\$ 35,213,721</b>	<b>\$ 29,674,610</b>
<b>Liabilities</b>			
Current Liabilities:			
Accounts payable and accrued liabilities		\$ 4,439,591	\$ 2,218,352
Warrant liability	2b, 5	18,749,143	17,849,460
<b>Total Liabilities</b>		<b>23,188,734</b>	<b>20,067,812</b>
<b>Shareholders' Equity</b>			
Share Capital	4a	170,253,262	154,016,519
Contributed Surplus		6,298,717	5,146,784
Warrants	4b	-	741,917
Deficit		(164,526,992)	(150,298,422)
<b>Total Equity</b>		<b>12,024,987</b>	<b>9,606,798</b>
<b>Total liabilities and equity</b>		<b>\$ 35,213,721</b>	<b>\$ 29,674,610</b>

Commitments (Note 6)

See notes to financial statements

Approved on behalf of the Board:

\_\_\_\_\_  
**John E. Barker**  
Chairman

\_\_\_\_\_  
**David McNally**  
President and CEO

**TITAN MEDICAL INC.**  
**Unaudited Condensed Interim Statement of Shareholders' Equity and Deficit**  
**For the Periods Ended September 30, 2018 and 2017**  
**(In U.S. Dollars)**

	Share Capital Number	Share Capital Amount	Contributed Surplus	Warrants	Deficit	Total Equity
Balance - December 31, 2016	5,550,382	\$ 112,742,810	\$ 3,707,432	\$ 855,800	\$ (116,711,438)	\$ 594,604
Issued pursuant to agency agreement	2,699,094	12,547,765				12,547,765
Issued private placement	563,067	1,887,411				1,887,411
Warrant liability issued during the period		(4,661,928)				(4,661,928)
Share issue expense		(926,709)				(926,709)
Warrants exercised during the period	529,251	5,020,022				5,020,022
Warrants expired during the period		113,883		(113,883)		-
Stock based compensation			1,024,574			1,024,574
Net and Comprehensive loss for the period					(20,757,004)	(20,757,004)
<b>Balance - September 30, 2017</b>	<b>9,341,794</b>	<b>\$ 126,723,254</b>	<b>\$ 4,732,006</b>	<b>\$ 741,917</b>	<b>\$ (137,468,442)</b>	<b>\$ (5,271,265)</b>
Balance - December 31, 2017	12,686,723	154,016,519	5,146,784	741,917	(150,298,422)	9,606,798
Issued pursuant to agency agreement	8,975,126	28,424,732				28,424,732
Warrant liability issued during the period		(11,509,338)				(11,509,338)
Share issue expense		(1,546,800)				(1,546,800)
Issued Other	7,500	66,234				66,234
Warrants exercised during the period	6,500	59,998				59,998
Warrants expired during the period		741,917		(741,917)		-
Stock based compensation			1,151,933			1,151,933
Net and Comprehensive loss for the period					(14,228,570)	(14,228,570)
<b>Balance - September 30, 2018</b>	<b>21,675,849</b>	<b>\$ 170,253,262</b>	<b>\$ 6,298,717</b>	<b>\$ -</b>	<b>\$ (164,526,992)</b>	<b>\$ 12,024,987</b>

See notes to financial statements

**TITAN MEDICAL INC.****Unaudited Condensed Interim Statement of Net and Comprehensive Loss****For the Three and Nine Months Ended September 30, 2018 and 2017****(In U.S. Dollars)**

	Note	Three months ended September 30,		Nine months ended September 30,	
		2018	2017	2018	2017
<b>Revenue:</b>		\$ -	\$ -	\$ -	\$ -
<b>Expenses:</b>					
Amortization		5,371	2,527	22,485	13,312
Consulting fees		134,009	132,753	505,197	403,186
Stock based compensation	4(b)	428,528	400,892	1,151,933	1,024,574
Insurance		120,434	5,533	136,391	18,997
Management salaries and fees		622,910	623,819	2,062,909	1,870,574
Marketing and investor relations		55,395	77,479	226,393	243,316
Office and general		110,106	55,060	344,733	222,561
Professional fees		142,299	80,507	466,766	377,157
Rent		23,602	26,974	73,395	77,228
Research and Development		9,143,987	4,061,695	18,664,336	9,712,072
Travel		64,430	67,251	250,327	224,627
Foreign exchange (gain)/loss		286,152	194,157	(646,245)	274,721
		11,137,223	5,728,647	23,258,620	14,462,325
<b>Finance Income (cost):</b>					
Interest		93,894	3,356	176,877	8,764
Gain (Loss) on change in fair value of warrants	2(b), 5	4,075,833	(8,099,030)	9,928,944	(5,726,557)
Warrant liability issue cost		(566,960)	(78,496)	(1,075,771)	(576,886)
		3,602,767	(8,174,170)	9,030,050	(6,294,679)
<b>Net and Comprehensive Loss</b>		<b>\$ 7,534,456</b>	<b>\$ 13,902,817</b>	<b>\$ 14,228,570</b>	<b>\$ 20,757,004</b>
<b>Basic and Diluted Loss Per Share</b>		<b>\$ 0.41</b>	<b>\$ 1.65</b>	<b>\$ 0.95</b>	<b>\$ 3.05</b>
<b>Weighted Average Number of Common Shares, Basic and Diluted</b>		<b>18,253,430</b>	<b>8,410,063</b>	<b>14,936,375</b>	<b>6,800,328</b>

See notes to financial statements

**TITAN MEDICAL INC.**  
**Unaudited Condensed Interim Statements of Cash Flows**  
**For the Three and Nine Months Ended September 30, 2018 and 2017**  
**(In U.S. Dollars)**

	Three months ending September 30,		Nine months ending September 30,	
	2018	2017	2018	2017
Cash provided by (used in):				
<b>Operating activities:</b>				
Net loss for the period	\$ (7,534,456)	\$ (13,902,817)	\$ (14,228,570)	\$ (20,757,004)
Items not involving cash:				
Amortization	5,371	2,527	22,485	13,312
Stock based compensation	428,528	400,892	1,151,933	1,024,574
Other share compensation	-	-	66,234	-
Warrant liability-fair value adjustment	(4,075,833)	7,389,248	(9,928,944)	5,016,775
Warrant liability-foreign exchange adjustment	283,894	170,553	(651,762)	221,742
Loss on extinguishment of other liabilities	-	709,782	-	709,782
<b>Changes in non-cash working capital items:</b>				
Amounts receivable, prepaid expenses and deposits	(444,935)	231,729	(2,263,365)	(496,957)
Accounts payable and accrued liabilities	250,756	(674,100)	2,221,239	701,473
Cash used in operating activities	(11,086,675)	(5,672,186)	(23,610,750)	(13,566,303)
<b>Financing activities:</b>				
Net proceeds from issuance of common shares and warrants	18,051,242	3,719,490	26,908,982	14,220,805
Cash provided by financing activities	18,051,242	3,719,490	26,908,982	14,220,805
<b>Investing Activities:</b>				
Increase in furniture and equipment	-	-	-	(3,427)
Cost of Patents	(100,867)	(81,943)	(197,906)	(187,267)
Cash used in investing activities	(100,867)	(81,943)	(197,906)	(190,694)
Increase (decrease) in cash and cash equivalents	6,863,700	(2,034,639)	3,100,326	463,808
Cash and cash equivalents, beginning of period	22,367,119	6,838,358	26,130,493	4,339,911
Cash and cash equivalents, end of period	\$ 29,230,819	\$ 4,803,719	\$ 29,230,819	\$ 4,803,719
Cash and cash equivalents comprise:				
Cash	\$ 261,935	\$ 2,556,533	\$ 261,935	\$ 2,556,533
Cash Equivalents	28,968,884	2,247,186	28,968,884	2,247,186
	\$ 29,230,819	\$ 4,803,719	\$ 29,230,819	\$ 4,803,719

See notes to financial statements

**1. DESCRIPTION OF BUSINESS**

**Nature of Operations:**

The Company's business continues to be in the research and development stage and is focused on the continued research and development of the next generation surgical robotic platform. In the near term, the Company will continue efforts to complete product development and proceed to pre-clinical and confirmatory human studies and satisfaction of appropriate regulatory requirements. Upon receipt of regulatory approvals, the Company will transition from the research and development stage to the commercialization stage. The completion of these latter stages will be subject to the Company receiving additional funding in the future.

The Company is incorporated in Ontario, Canada in accordance with the Business Corporations Act. The address of the Company's corporate office and its principal place of business is Toronto, Canada.

**Basis of Preparation:**

**(a) Statement of Compliance**

These condensed interim financial statements for the three and nine months ending September 30, 2018 have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting ("IAS 34").

These condensed interim financial statements should be read in conjunction with the Company's 2017 annual financial statements which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

The condensed interim financial statements have been prepared using accounting policies consistent with those used in the Company's 2017 annual financial statements as well as any amendments, revisions and new IFRS, which have been issued subsequently and are appropriate to the Company.

The condensed interim financial statements were authorized for issue by the Board of Directors on November 12, 2018.

**(b) Basis of Measurement**

These condensed interim financial statements have been prepared on the historical cost basis except for the revaluation of the warrant liability, which is measured at fair value.

**(c) Functional and Presentation Currency**

These condensed interim financial statements are presented in United States dollars ("U.S."), which is the Company's functional and presentation currency.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**(a) Use of Estimates and Judgements**

The preparation of financial statements in conformity with IAS 34, Interim Financial Reporting requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of provisions at the date of the condensed interim financial statements and the reported amount of expenses during the year. Financial statement items subject to significant judgement include, the measurement of stock based compensation and the fair

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (continued)

value estimate of the initial measurement of new warrant liabilities and the remeasurement of unlisted warrant liabilities. While management believes that the estimates and assumptions are reasonable, actual results may differ.

In assessing whether the going concern assumption is appropriate, management considers all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. The Company expects that approximately US \$30 million in incremental funding is needed, for the next 12 months to maintain its currently anticipated pace of development. If additional funding is not available, the pace of the Company's product development plan may be reduced. However, based on internal forecasts, Management believes that the Company has sufficient funds to meet its obligations under a reduced development plan, if necessary, for the ensuing twelve months.

**Fair Value**

The Black-Scholes model used by the Company to determine fair values of stock options and warrants was developed for use in estimating the fair value of the stock options and warrants.

**(b) Warrant Liability**

In accordance with IAS 32, because the exercise prices of warrants issued are not a fixed amount as they are denominated in a currency (Canadian dollars) other than the Company's functional currency (U.S. dollar), as well as the warrants issued August 10, 2018 with the cashless exercise options, the warrants are accounted for as a derivative financial liability. Each Warrant Liability is initially measured at fair value and subsequent changes in fair value are recorded through Net and Comprehensive Loss for the year. The fair value of these warrants was determined initially using a comparable warrant quoted in an active market, adjusted for differences in the terms of the warrant. At September 30, 2018, the Warrant Liability of listed warrants was adjusted to fair value measured at the market price of the listed warrants, the unlisted warrants were adjusted to fair value using the Black-Scholes formula.

**(c) Fair Value Measurement**

The accounting guidance for fair value measurements prioritizes the inputs used in measuring fair value into the following hierarchy:

**Level 1** – Quoted prices (unadjusted) in active markets for identical assets or liabilities;

**Level 2** – Inputs other than quoted prices included within Level 1 that are directly or indirectly observable:

**Level 3** – Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

The fair value of the listed and unlisted Warrant liability is initially based on level 2 significant observable inputs and at September 30, 2018 is based on level 1, quoted prices (unadjusted) for listed warrants and level 2 for unlisted warrants.

**TITAN MEDICAL INC.**  
**Notes to the Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018**  
**(In U.S. Dollars)**

---

2. **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (continued)

**New accounting standards applied**

**IFRS 9 Financial Instruments**

Effective January 1, 2018, the Company adopted IFRS 9, "Financial Instruments", which replaced IAS 39, "Financial Instruments: Recognition and Measurement". The adoption of IFRS 9 did not have a material impact on the measurement and carrying values of the Company's financial instruments, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and warrant liability.

3. **PATENT RIGHTS**

**Cost**

Balance at December 31, 2017	\$	978,126
Additions		<u>197,906</u>
Balance at September 30, 2018	\$	1,176,032

**Amortization**

Balance at December 31, 2017	\$	203,901
Amortization for the period		<u>15,771</u>
Balance at September 30, 2018	\$	219,672

**Net Book Value**

At December 31, 2017	\$	<u>774,225</u>
At September 30, 2018	\$	<u>956,360</u>

4. **SHARE CAPITAL**

<b>a)</b>	<b>Authorized:</b>	unlimited number of common shares, no par
	<b>Issued:</b>	21,675,849 (December 31, 2017: 12,686,723)

Exercise prices of units, warrants and options are presented in Canadian currency as they are exercisable in Canadian dollars unless otherwise noted.

On June 19, 2018 a share consolidation of 1:30 was completed and the Company's outstanding common shares were adjusted from 419,888,250 to 13,996,275. All references to the common shares, warrants and stock options, prior to the share consolidation, have been updated in the notes to reflect the 1:30 reverse stock split.

On August 10, 2018 Titan Completed an offering of securities made pursuant to an agency agreement dated August 7, 2018 between the Company and Bloom Burton Securities Inc. (the "Agent"). The Company sold 7,679,574 Units under the Offering price of US \$2.50 per Unit for gross proceeds of approximately \$19,198,935 (\$17,470,398 net of closing cost including cash commission of \$1,343,925). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of US \$3.20 and expiring August 10, 2023. The warrants were valued at \$6,297,251 based on the value determined by the Black-Scholes model and the balance of \$12,901,684 was allocated to common shares.

**TITAN MEDICAL INC.**  
**Notes to the Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018**  
**(In U.S. Dollars)**

---

4. **SHARE CAPITAL** (continued)

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 537,570 Common Shares at a price of USD \$2.50 per share prior to expiry on August 10, 2020.

On April 10, 2018 Titan completed an offering of securities made pursuant to an agency agreement dated April 3, 2018 between the Company and Bloom Burton Securities Inc. The Company sold 1,126,665 Units under the Offering at a price of CDN \$9.00 per Unit for gross proceeds of approximately \$8,035,941 (\$7,211,320 net of closing costs including cash commission of \$562,516). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$10.50 and expiring April 10, 2023. The warrants were valued at \$4,553,700 based on the value determined by the Black-Scholes model and the balance of \$3,482,241 was allocated to common shares.

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 78,867 Common Shares at a price of CDN \$9.00 per share prior to expiry on April 10, 2020.

On May 10, 2018 Titan announced the completion of the over-allotment option granted to Bloom Burton Securities Inc. as agent for its offering at a price of CDN \$9.00 per Unit completed on April 10, 2018 was exercised and the Company sold an additional 168,889 Units at the offering price for additional gross proceeds of \$1,189,856 (\$1,100,238 net of closing costs including cash commission of \$76,988). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$10.50 and expiring April 10, 2023. The warrants were valued at \$658,387 based on the value determined by the Black-Scholes model and the balance of \$531,469 was allocated to common shares.

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 10,928 Common Shares at a price of CDN \$9.00 per share prior to expiry on April 10, 2020.

During the year ended December 31, 2017, 1,755,141 warrants had been exercised for total proceeds of \$9,438,577. The fair value of the exercised warrants had a value of \$7,953,581 which was reclassified from warrant liability to common stock.

On December 5, 2017 Titan completed an offering of securities made pursuant to an agency agreement dated November 30, 2017 between the Company and Bloom Burton Securities Inc. The company sold 1,533,333 Units under the Offering at a price of CDN \$15 per Unit for gross proceeds of approximately \$18,137,800 (\$16,555,875 net of closing costs including cash commission of \$1,246,185 paid in accordance with the terms of the agency agreement). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$18.00 and expiring December 5, 2022. The warrants were valued at \$5,223,686 based on the value determined by the Black-Scholes model and the balance of \$12,914,114 was allocated to common shares.

Pursuant to the agency agreement in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 105,350 Common Shares at a price of CDN \$15.00 per share prior to expiry on December 5, 2019.

**TITAN MEDICAL INC.**  
**Notes to the Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018**  
**(In U.S. Dollars)**

---

4. SHARE CAPITAL (continued)

On October 31, 2017 Titan completed the final closing of a private placement led by a group of U.S. robotic surgeons. 446,197 common shares of Titan were issued at a subscription price of CDN \$7.50 per Common Share for gross proceeds of \$2,677,326.

On June 29, 2017 Titan completed an offering of securities made pursuant to an agency agreement dated June 26, 2017 between the Company and Bloom Burton Securities Inc. The Company sold 1,612,955 Units under the Offering at a price of CDN \$4.50 per Unit for gross proceeds of approximately \$5,576,357 (\$4,838,002 net of closing costs including cash commission of \$382,689 paid in accordance with the terms of the agency agreement). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$6.00 and expiring June 29, 2022. The warrants were valued at \$2,788,274 based on the value determined by the Black-Scholes model and the balance of \$2,788,083 was allocated to common shares.

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 109,533 Common Shares at a price of CDN \$4.50 per share prior to expiry on June 29, 2019.

On July 21, 2017 Titan completed a second closing of an offering of securities made pursuant to an agency agreement dated June 26, 2017 between the Company and Bloom Burton Securities Inc. The Company sold an additional 370,567 Units under the Offering at a price of CDN \$4.50 per Unit for gross proceeds of approximately \$1,328,871 (\$1,200,788 net of closing costs including cash commission of \$93,021 paid in accordance with the terms of the agency agreement). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$6.00 and expiring June 29, 2022. The warrants were valued at \$575,844 based on the value determined by the Black-Scholes model and the balance of \$753,027 was allocated to common shares.

Pursuant to the agency agreement in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 25,940 Common Share at a price of CDN \$4.50 per share prior to expiry on June 29, 2019.

On March 16, 2017 Titan completed an offering of securities made pursuant to an agency agreement dated March 10, 2017 between the Company and Bloom Burton Securities Inc. The Company sold 715,573 Units under the Offering at a price of CDN \$10.50 per Unit for gross proceeds of approximately \$5,642,537 (\$5,039,817 net of closing costs including cash commission of \$394,316 paid in accordance with the terms of the agency agreement). Each Unit consisted of one Common Share of the Company and (i) one-half of one Common Share purchase warrant, each whole warrant entitling the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$12.00 and expiring March 16, 2019, and (ii) one-half of one Common Share purchase warrant, each whole warrant entitling the holder thereof to acquire on Common Share of the Company at an exercise price of CDN \$15 and expiring March 16, 2021. The warrants were valued at \$1,297,810 based on the value determined by the Black-Scholes model and the balance of \$4,344,727 was allocated to common shares.

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 50,005 Common Shares at a price of CDN \$10.50 per share prior to expiry on March 16, 2019.

**TITAN MEDICAL INC.**  
**Notes to the Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018**  
**(In U.S. Dollars)**

---

**4. SHARE CAPITAL** (continued)

On November 23, 2015 Titan closed a private placement of 143,009 Common Shares to Longtai Medical Inc. at a subscription price of CDN \$36.90 per common share for gross proceeds of \$4,000,000. Under the Agreement, Titan granted to Longtai exclusive rights to negotiate an exclusive marketing, sales and distribution agreement for Titan’s SPORT Surgical System in the Asia Pacific region. Longtai paid to Titan \$2,000,000 as a deposit toward the Distribution Agreement.

As the parties were not able to reach consensus as to the Distribution Agreement by the agreed upon date, the deposit became due for repayment to Longtai. On August 24, 2017 Titan completed a subscription agreement with Longtai for the equity conversion of Longtai’s \$2.0 million deposit. Under the terms of the subscription agreement dated July 31, 2017, Titan issued to Longtai 563,067 Units at an assigned issue price of CDN \$4.50 per Unit. Each Unit consists of one common share and one common share purchase warrant, with each warrant exercisable for one Common Share at an exercise price of CDN \$6 per warrant and will expire August 24, 2022. The warrants were valued at \$822,372 based on the value determined by the Black-Scholes model.

The common shares were valued at \$1,887,411 based on the market value on August 24, 2017 of CDN \$4.20. The warrant and the common share were valued at fair value in accordance with International Financial Reporting Interpretations Committee Interpretation #19-Extinguishing Financial Liabilities (“IFRIC 19”). A loss of \$709,782 was incurred on extinguishment which is included in the Gain (Loss) on change in value of warrant liability in the statement of net and comprehensive loss.

**b) Warrants, Stock Options and Compensation Options**

Titan has reserved and set aside up to 10% of the issued and outstanding shares of Titan for granting of options to employees, officers, consultants and advisors. At September 30, 2018, 1,277,224 common shares (September 30, 2017: 371,240) were available for issue in accordance with the Company’s stock option plan. The terms of these options are determined by the Board of Directors. A summary of the status of the Company’s outstanding stock options as of September 30, 2018 and September 30, 2017 and changes during the periods ended on those dates is presented in the following table:

	<b>Nine Months Ended September 30, 2018</b>		<b>Nine Months Ended September 30, 2017</b>	
	<u>Number of Stock Options</u>	<u>Weighted-average Exercise Price (CDN)</u>	<u>Number of Stock Options</u>	<u>Weighted-average Exercise Price (CDN)</u>
Balance Beginning	591,609	\$21.30	240,075	\$33.00
Granted	322,517	\$13.51	366,161	\$15.68
Expired/Forfeited	<u>(23,765)</u>	<u>\$17.36</u>	<u>(43,296)</u>	<u>\$34.93</u>
Balance Ending	<b><u>890,361</u></b>	<b><u>\$18.51</u></b>	<b><u>562,940</u></b>	<b><u>\$21.58</u></b>

**TITAN MEDICAL INC.**  
**Notes to the Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018**  
**(In U.S. Dollars)**

---

4. ***SHARE CAPITAL*** (continued)

The weighted-average remaining contractual life and weighted-average exercise price of options outstanding and of options exercisable as at September 30, 2018 are as follows:

<b>Options Outstanding</b>			
Exercise Price (CDN)	Number Outstanding	Weighted-average remaining contractual life (years)	Options Exercisable
\$3.28	31,498	6.92	31,498
\$4.50	18,935	4.91	18,935
\$4.80	3,040	1.96	3,040
\$7.49	5,590	6.77	5,590
\$9.00	11,481	6.77	11,481
\$9.60	1,105	2.02	1,105
\$11.70	6,667	2.18	3,333
\$12.00	1,948	2.18	1,948
\$12.90	50,000	5.55	12,500
\$14.40	18,950	6.11	-
\$15.00	16,667	5.36	4,167
\$15.00	273,948	6.31	-
\$17.10	277,519	5.30	69,380
\$28.80	10,170	0.22	10,170
\$30.00	105,719	2.90	81,462
\$30.60	6,120	2.23	4,889
\$32.40	18,810	2.33	18,810
\$41.70	658	1.21	658
\$45.30	560	1.87	560
\$51.60	15,371	1.69	15,371
\$52.80	3,537	0.43	3,537
\$58.20	12,069	0.64	12,069
	<b>890,361</b>	<b>5.10</b>	<b>310,503</b>

The weighted average exercise price of options outstanding is CDN \$18.51 and CDN \$22.74 for options that are exercisable.

**TITAN MEDICAL INC.**  
**Notes to the Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018**  
**(In U.S. Dollars)**

**4. SHARE CAPITAL** (continued)

Options are granted to Directors, Officers, Employees and Consultants at various times. Options are to be settled by physical delivery of shares.

<b>Grant date/Person entitled</b>	<b>Number of Options</b>	<b>Vesting Conditions</b>	<b>Contractual life of Options</b>
January 17, 2017, option grants to Employees	277,519	Vest as to ¼ of the total number of Options granted, every year from Option Date	7 years
February 7, 2017 option grants to Employees	16,667	Vest as to 1/4 of the total number of Options granted, every year from Option Date	7 years
April 17, 2017, option grants to Employees	50,000	Vest as to 1/4 of the total number of Options granted, every year from Option Date	7 years
September 7, 2017, options granted to Consultants	6,667	Half vest in 3 months and the remaining half in 6 months	3 years
September 7, 2017, options granted to Directors	12,269	immediately	7 years
September 15, 2017, options granted to Consultants	3,040	immediately	3 years
October 6, 2017, options granted to Consultants	1,105	immediately	3 years
November 8, 2017 option grants to Employees	18,950	Vest as to 1/4 of the total number of Options granted, every year from Option Date	7 years
December 4, 2017, options granted to Consultants	1,948	immediately	3 years
December 4, 2017, options granted to Consultants	6,667	Half vest immediately and the remaining half in 12 months	3 years
January 19, 2018 option grants to Employees	273,948	Options will vest the earlier of commercialization or 3 years from grant date.	7 years
July 6, 2018, options granted to Directors	17,071	immediately	7 years
August 29, 2018, options granted to Directors	31,498	immediately	7 years

**Inputs for Measurement of Grant Date Fair Values**

The grant date fair value of all share-based payment plans was measured based on the Black-Scholes formula. Expected volatility was estimated by considering historic average share price volatility. The inputs used in the measurement of fair values at grant date of the share-based option plan are as follows:

	<u>2018</u>	<u>2017</u>
Fair Value at grant date (CDN)	\$1.44 - \$ 7.50	\$ 2.40 - \$ 9.60
Share price at grant date (CDN)	\$2.57 - \$13.80	\$ 4.50 - \$16.20
Exercise price (CDN)	\$3.28 - \$15.00	\$ 4.50 - \$17.10
Expected Volatility	88.1% - 96%	82.4% - 83.3%
Option Life	3 years	3 - 4 years
Expected dividends	nil	nil
Risk-free interest rate (based on government bonds)	1.86% - 2.16%	0.89% - 1.63%

**TITAN MEDICAL INC.**  
**Notes to the Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018**  
**(In U.S. Dollars)**

**4. SHARE CAPITAL** (continued)

The following is a summary of outstanding warrants included in Shareholder's Equity as at September 30, 2018 and September 30, 2017 and changes during the periods then ended.

	Nine Months Ended September 30, 2018		Nine Months Ended September 30, 2017	
	Number of Warrants	Amount	Number of Warrants	Amount
Opening Balance	175,357	\$ 741,917	188,381	\$ 855,800
Expired during the year Exercise Price CDN \$1.25 Expiry March 18, 2018	(175,357)	(741,917)	-	-
Expired during the year Exercise Price CDN \$1.77 Expiry March 14, 2017	-	-	(13,024)	(113,883)
<b>Ending Balance</b>	<b>-</b>	<b>\$ -</b>	<b>175,357</b>	<b>\$ 741,917</b>

**5. WARRANT LIABILITY**

	Nine Months Ended September 30, 2018		Year Ended December 31, 2017	
	Number of Warrants	Amount	Number of Warrants	Amount
Opening Balance	4,933,231	\$ 17,849,460	2,581,703	\$ 2,365,691
Issue of warrants expiring, March 16, 2019	-	-	357,787	572,326
Issue of warrants expiring, March 16, 2021	-	-	357,787	725,484
Issue of warrants expiring, June 29, 2022	-	-	1,983,522	3,364,118
Issue of warrants expiring, August 24, 2022	-	-	563,067	822,372
Issue of warrants expiring, December 5, 2022	-	-	1,533,333	5,223,686
Issue of warrants expiring, April 10, 2023	1,295,554	5,212,087	-	-
Issue of warrants expiring, August 10, 2023	7,679,574	6,297,251	-	-
Warrants exercised during the year	(6,500)	(28,949)	(1,755,142)	(7,953,581)
Warrants expired during the year	-	-	(688,826)	-
Foreign exchange adjustment during the year	-	(651,762)	-	305,475
Fair value adjustment during the year	-	(9,928,944)	-	12,423,889
<b>Ending Balance</b>	<b>13,901,859</b>	<b>\$ 18,749,143</b>	<b>4,933,231</b>	<b>\$ 17,849,460</b>

In addition to the warrants listed above, at September 30, 2018, the Company has issued and outstanding, 790,920 broker unit warrants expiring between October 27, 2018 and August 10, 2020.

**TITAN MEDICAL INC.**  
**Notes to the Unaudited Condensed Interim Financial Statements**  
**Three and Nine Months Ended September 30, 2018**  
**(In U.S. Dollars)**

---

**6. COMMITMENTS**

The Company has 4,477 square feet leased at a former location for CDN \$4,673 per month through January 31, 2019. This space has been sublet for CDN \$4,099 per month through the lease term.

For its corporate office located at 170 University Avenue, Toronto Ontario, effective September 18, 2017 the Company extended its lease term for a period of 22 months, commencing February 1, 2018 at a monthly rent of CDN \$9,969.

As a part of its program of research and development around the SPORT Surgical System, the Company has outsourced certain aspects of the design and development to a U.S. based technology and development company. At September 30, 2018 \$14,490,933 in purchase orders remain outstanding. The Company also has on deposit with this same U.S. supplier \$4,278,850 to be applied against future invoices.

**7. RELATED PARTY TRANSACTIONS**

During the three months and nine months ended September 30, 2018, transactions between the Company and directors, officers and other related parties were related to compensation matters in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

Compensation to the Executive Officers amounted to \$322,792 and \$1,240,904 for the three and nine months ended September 30, 2018 compared to \$409,227 and \$1,165,759 for the same period in 2017.

Officers and Directors of the Company control approximately 0.25% of the Company

	September 30, 2018		December 31, 2017	
	Number of Shares	%	Number of Shares	%
John Barker	23,714	0.11	23,714	0.19
Martin Bernholtz	-	-	102,383	0.81
David McNally	4,167	0.02	1,667	0.01
Stephen Randall	18,243	0.08	11,910	0.09
John Schellhorn	294	-	294	-
Bruce Wolff	7,610	0.04	2,010	0.02
<b>Total</b>	<b>54,028</b>	<b>0.25</b>	<b>141,978</b>	<b>1.12</b>
Common Shares Outstanding	<b>21,675,849</b>	<b>100%</b>	<b>12,686,723</b>	<b>100%</b>